In aggressive CLL, EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC, thus regulating glycolysis, glutaminolysis and mitochondrial biogenesis [151, 152]. This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.